Delivery Order SPE2DB22D1017-SPE2DB25FG5CV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,126.74 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose tablets) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed price contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $999,999,999.00 and running through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $7,463.51 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of UBRELVY 100 MG tablets (unit dose, 10-count packages). This firm fixed price delivery order, which is not set-aside designated, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $2,164.44 to AmerisourceBergen Drug Corp for the supply of UBRELVY 100 mg tablets (10-count unit dose packaging) on September 19, 2025, with completion expected by September 22, 2025. This competitively awarded, non-set-aside firm fixed price delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,201.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose packs) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract is being performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a $27,906.58 firm fixed price delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-unit dose packages) with an ultimate completion date of September 25, 2025. This non-set-aside award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, where the vendor maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,856.58 to AmerisourceBergen Drug Corp for UBRELVY 50 MG tablets (10 unit doses) on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract under the company's broader pharmaceutical supply agreement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $3,420.49 to AmerisourceBergen Drug Corp for the supply of UBRELVY (an FDA-approved migraine treatment) in 100 mg tablet form on August 20, 2025, with completion expected by August 21, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $4,332.86 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of UBRELVY (an oral migraine treatment) in 100 mg tablet form, with an ultimate completion date of April 24, 2025. This is a non-set-aside, competitively awarded delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG5CVDelivery Order
The Defense Logistics Agency awarded a $1,146.60 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose tablets) on June 17, 2025, with completion scheduled for June 18, 2025. This firm fixed-price, competitively awarded contract utilizes no set-aside designation and identifies Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through its comprehensive IDC vehicle. This delivery order for UBRELVY, a migraine treatment medication, exemplifies the company's role supplying brand-name and generic medications across multiple therapeutic domains to support military and federal healthcare programs. The underlying IDC functions as a flexible pharmaceutical support vehicle enabling AmerisourceBergen to deliver a broad range of specialty medications, vaccines, and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 6/17/25 |